| Literature DB >> 29179678 |
Yusuke Mitsuka1, Yutaka Midorikawa2, Hayato Abe1, Naoki Matsumoto3, Mitsuhiko Moriyama3, Hiroki Haradome4, Masahiko Sugitani5, Shingo Tsuji6, Tadatoshi Takayama1.
Abstract
BACKGROUND: Liver stiffness measurement (LSM) has recently become available for assessment of liver fibrosis. We aimed to develop a prediction model for liver fibrosis using clinical variables, including LSM.Entities:
Keywords: Liver fibrosis; Liver stiffness measurement; Magnetic resonance elastography; Prediction model
Mesh:
Substances:
Year: 2017 PMID: 29179678 PMCID: PMC5704624 DOI: 10.1186/s12876-017-0700-z
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Fig. 1Flow diagram describing patient recruitment and follow-up
Patient characteristics
| Characteristic | Patients ( |
|---|---|
| Age, yr | 69 (42–91) |
| Male, n (%) | 130 (70.6) |
| Background liver disease, | |
| Non-B non-C liver | 103 (55.9) |
| Hepatitis B | 35 (19.0) |
| Hepatitis C | 46 (25.0) |
| Body mass index, kg/m2 | 22.8 (14.4–37.1) |
| ASA grading, n (%) | |
| Grade 1 | 65 (35.3) |
| Grade 2 | 116 (63.0) |
| Grade 3 | 3 (1.6) |
| History of hepatic resection, n (%) | 48 (26.0) |
| Hemoglobin, g/dL | 13.0 (8.2–16.9) |
| White blood cell count, 109/L | 5.1 (2.3–12.1) |
| Platelet count, 109/L | 17.2 (4.8–43.5) |
| Total bilirubin, mg/dL | 0.59 (0.24–1.48) |
| Aspartate aminotransferase, U/L | 28 (11–170) |
| Alanine aminotransferase, U/L | 23 (6–271) |
| PT-INR | 0.99 (0.85–1.36) |
| Albumin, g/L | 3.9 (2.3–4.8) |
| Hyaluronic acid, ng/mL | 62 (12–737) |
| IV core 7S, ng/mL | 5.8 (3.2–13.0) |
| Child-Pugh classification, n (%) | |
| A | 178 (96.7) |
| B | 6 (3.2) |
| ICGR15, % | 12.2 (3.4–33.0) |
| LSM value by MRE, kPa | 3.3 (1.4–11.2) |
Data were presented as median (range), if not specified
ASA indicates American Society of Anesthesiology, PT-INR Prothrombin time-International normalized ratio, ICGR15 Indocyanine green clearance rate at 15 min, LSM Liver stiffness measurement, MRE Magnetic resonance elastography
Diseases for liver resection
| Disease, | Patients ( |
|---|---|
| Hepatocellular carcinoma | 107 (58.1) |
| Intrahepatic cholangiocarcinoma | 11 (5.9) |
| Hilar bile duct cancer | 4 (2.1) |
| Gallbladder cancer | 4 (2.1) |
| Cystoadenocarcinoma | 1 (0.5) |
| Metastatic liver cancera | 57 (30.9) |
aFrom 57 colorectal cancer, two gastric cancer, two pancreatic cancer, and one neuroendocrine tumor
Liver pathology
| Patients ( | |
|---|---|
| Steatosis, n (%) | |
| 0 (0%) | 129 (70.1) |
| 1 (1 to 33%) | 44 (23.9) |
| 2 (33 to 66%) | 10 (5.4) |
| 3 (66 to 100%) | 1 (0.5) |
| Lobular inflammation, n (%) | |
| A0 (no necro-inflammatory reaction) | 41 (22.2) |
| A1 (mild) | 99 (53.8) |
| A2 (moderate) | 43 (23.3) |
| A3 (severe) | 1 (0.5) |
| Fibrosis, n (%) | |
| F0 (no fibrosis) | 44 (23.9) |
| F1 (fibrous portal expansion) | 59 (32.0) |
| F2 (bridging fibrosis) | 26 (14.1) |
| F3 (bridging fibrosis with architectural distortion) | 26 (14.1) |
| F4 (liver cirrhosis) | 29 (15.7) |
Fig. 2Distribution of LSM by MRE, ICGR15, and platelet count, and liver fibrosis as shown by box plots. There were significant correlations between LSM (a), ICGR15 (b), and platelet count (c) and the pathological grade of liver fibrosis
Fig. 3Distributions of fibrosis score and fibrosis grade. a Distributions of fibrosis score and fibrosis grade in the 122 patients in the training group (r = 0.712, P < 0.001). b Distributions of fibrosis score and fibrosis grade in the 62 patients in the test group (r = 0.725, P < 0.001)